GEN Exclusives

More »

GEN News Highlights

More »
Apr 21, 2011

Icon and Acronet to Collaborate on Clinical Trial Management

  • Icon and Acronet will work together to offer clients a range of clinical development capabilities to manage trials on a regional or global basis. The Japanese firms say that the agreement was established because of the rising need from their clients in the country and outside for clinical trial management services.

    “Recent changes in the regulatory landscape mean that an increasing number of Japanese-based pharmaceutical companies are looking to run development projects on both a domestic and pan-regional basis,” says Alan Morgan, Icon’s group president, clinical research services.

    “The number of global clinical trials involving the triad regions of U.S., EU, and Japan has increased gradually in recent years and this trend will continue to accelerate,” notes Shogo Nakamori, Acronet’s president and CEO. “This is one of the challenging areas for the Japanese pharmaceutical industry, and Acronet is now ready to contribute and support the above challenging areas through this alliance with Icon.”

    With headquarters in Tokyo and additional offices in Osaka, Fukuoka, and New York, Acronet employs around 500 clinical development professionals. Icon has been operational in Japan since 1995 and offers a variety of clinical development services and contract staffing from its offices in Tokyo and Osaka.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Alzheimer's Therapies

Do you think an effective treatment for Alzheimer’s will be found within the next 10–15 years?